Transcend Medical Obtains $16,000,000 Series B Funding Round

  • Feed Type
  • Date
    7/15/2011
  • Company Name
    Transcend Medical
  • Mailing Address
    127 Independence Drive Menlo Park, CA 94025
  • Company Description
    Transcend Medical, Inc. is focused on the research and development of novel devices for the treatment of glaucoma, the leading cause of adult irreversible blindness. Over two million people in the U.S. alone are afflicted with the disease today and the numbers are expected to grow to three million by the year 2020. The Transcend Medical approach is focused on replacing the current therapies for the treatment of glaucoma with a less invasive procedure and minimal complications.
  • Website
    http://www.transcendmedical.com
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $16,000,000
  • Transaction Round
    Series B
  • Proceeds Purposes
    Transcend will use the funds for development of additional infrastructure and resources for its U.S. pivotal study of the CyPass Micro-Stent, (www.CompassClinicalStudy.com), as well as for ongoing international clinical trials and development of next generation glaucoma solutions.
  • M&A Terms
  • Venture Investor
    Investor Growth Capital
  • Venture Investor
    Canaan Partners
  • Venture Investor
    Latterell Venture Partners
  • Venture Investor
    Finistere Ventures
  • Venture Investor
    HLM Venture Partners
  • Venture Investor
    Kaiser Permanente Ventures
  • Venture Investor
    Morgenthaler Ventures
  • Venture Investor
    Split Rock Partners
  • Venture Investor
    Technology Partners

By posting a comment, you agree to our terms and conditions.